PAtients Like My gEnome (PALME) is a webservice that matches patients based on their genome and healthcare profiles. We support two types of inputs: (1) dual query (a variant + phenotype), and (2) genome sequences. For the first type of queries, we will show the patient profile matching the inputs. For the second type of queries, we will calculate similarity (based on Hamming distance) and show the distribution of phenotypes of similar patients given the input sequences of a target patient. Using the publicly available Personal Genome Project (PGP) dataset, we retrieved 4,360 patients' profiles along with their genome data, medical conditions, and treatments. We used a subset of these profiles to build PALME to be an interactive system to support healthcare profile matching. PALME is designed not only for biomedical researchers to support their studies on human genome but also for individuals to explore their own genetics and health. The webservice is accessible at (http://pgp.ucsd-dbmi.org:3838/GenAnaly/PatientGen/#) and the demo videos are available at (https://youtu.be/ycP0rXQizlc).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001758 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Identification, Clinical Values, and Prospective Pathway Signaling of Lipid Metabolism Genes in Epilepsy and AED Treatment.
Mol Neurobiol
January 2025
Department of Neurology, School of Medicine, Affiliated ZhongDa Hospital, Southeast University, Dingjiaqiao 87, Nanjing, 210009, Jiangsu, China.
The dysregulation of lipid metabolism has been associated with the etiology and progression of the neurological pathology. However, the roles of lipid metabolism and the molecular mechanism in epilepsy and the use of antiepileptic drugs (AEDs) are relatively understudied. Gene expression profiles of GSE143272 from blood samples were included for differential analysis, and the lipid metabolism-related differentially expressed genes (DEGs) were identified.
View Article and Find Full Text PDFPhase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205).
Ann Surg Oncol
January 2025
Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan.
Background: To improve the prognosis of clinically resectable type 4 or large type 3 gastric cancer (GC), we performed a phase I/II study of neoadjuvant-radiotherapy combined with S-1 plus cisplatin.
Patients And Methods: Phase I, with a standard 3 + 3 dose-escalation design, was performed to define the recommended phase II dose. Efficacy and safety were evaluated in phase II.
Retrospective discrimination of PNES and epileptic seizure types using blood RNA signatures.
J Neurol
January 2025
Morehouse School of Medicine, Neuroscience Institute, 720 Westview Drive SW, Atlanta, GA, 30310, USA.
Objectives: The ability to differentiate epileptic- and non-epileptic events is challenging due to a lack of reliable molecular seizure biomarker that provide a retrospective diagnosis. Here, we use next generation sequencing methods on whole blood samples to identify changes in RNA expression following seizures.
Methods: Blood samples were obtained from 32 patients undergoing video electroencephalogram (vEEG) monitoring.
Total functioning capacity scale in Huntington's disease: natural course over time.
J Neurol
January 2025
LUMC Department of Neurology, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Background And Objectives: The total functioning capacity (TFC) assessment has been integral to Huntington's disease (HD) research and clinical trials, measuring disease stage and progression. This study investigates the natural progression of function in HD, focusing on changes in TFC scores related to age and CAG-repeat length, and evaluates TFC's strengths and weaknesses in longitudinal studies.
Methods: Using Enroll-HD platform's clinical dataset version 5, including Registry-3, we analysed data from 21,079 participants, with 16,083 having an expanded CAG repeat.
RNA modification writer-based immunological profile and genomic landscape of tumor microenvironment in lung adenocarcinoma.
Discov Oncol
January 2025
Department of Oncology, Yanbian University Hospital, Yanji, 133000, China.
Background: Recent studies have highlighted the role of RNA modification, that is, the dysregulation of epitranscriptomics, in tumorigenesis and progression. The potential for undoing epigenetic changes may develop novel therapeutic and prognostic approaches. However, the roles of these RNA modifications in the tumor microenvironment (TME) are still unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!